List of Contents

Point-of-Care Diagnostics Market Size, Share, and Trends 2024 to 2034

The global point-of-care diagnostics market size was USD 60.52 billion in 2023, estimated at USD 62.28 billion in 2024 and is anticipated to reach around USD 82.78 billion by 2034, expanding at a CAGR of 2.89% from 2024 to 2034.

  • Last Updated : August 2024
  • Report Code : 1439
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Point of Care Diagnostics Market 

5.1. COVID-19 Landscape: Point of Care Diagnostics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Point of Care Diagnostics Market, By Product

8.1. Point of Care Diagnostics Market, by Product Type, 2024-2034

8.1.1. Blood Glucose Monitoring

8.1.1.1. Market Revenue and Forecast (2021-2034)

8.1.2. Infectious Diseases

8.1.2.1. Market Revenue and Forecast (2021-2034)

8.1.3. Cardiometabolic Diseases

8.1.3.1. Market Revenue and Forecast (2021-2034)

8.1.4. Pregnancy & Infertility Testing

8.1.4.1. Market Revenue and Forecast (2021-2034)

8.1.5. Hematology Testing

8.1.5.1. Market Revenue and Forecast (2021-2034)

8.1.6. Others

8.1.6.1. Market Revenue and Forecast (2021-2034)

Chapter 9. Global Point of Care Diagnostics Market, By End User

9.1. Point of Care Diagnostics Market, by End User, 2024-2034

9.1.1. Hospital Bedside

9.1.1.1. Market Revenue and Forecast (2021-2034)

9.1.2. Physician’s Office Lab

9.1.2.1. Market Revenue and Forecast (2021-2034)

9.1.3. Urgent Care & Retail Clinics

9.1.3.1. Market Revenue and Forecast (2021-2034)

9.1.4. Homecare/Self-testing

9.1.4.1. Market Revenue and Forecast (2021-2034)

Chapter 10. Global Point of Care Diagnostics Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Forecast, by Product (2021-2034)

10.1.2. Market Revenue and Forecast, by End User (2021-2034)

10.1.3. U.S.

10.1.3.1. Market Revenue and Forecast, by Product (2021-2034)

10.1.3.2. Market Revenue and Forecast, by End User (2021-2034)

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Forecast, by Product (2021-2034)

10.1.4.2. Market Revenue and Forecast, by End User (2021-2034)

10.2. Europe

10.2.1. Market Revenue and Forecast, by Product (2021-2034)

10.2.2. Market Revenue and Forecast, by End User (2021-2034)

10.2.3. UK

10.2.3.1. Market Revenue and Forecast, by Product (2021-2034)

10.2.3.2. Market Revenue and Forecast, by End User (2021-2034)

10.2.4. Germany

10.2.4.1. Market Revenue and Forecast, by Product (2021-2034)

10.2.4.2. Market Revenue and Forecast, by End User (2021-2034)

10.2.5. France

10.2.5.1. Market Revenue and Forecast, by Product (2021-2034)

10.2.5.2. Market Revenue and Forecast, by End User (2021-2034)

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Forecast, by Product (2021-2034)

10.2.6.2. Market Revenue and Forecast, by End User (2021-2034)

10.3. APAC

10.3.1. Market Revenue and Forecast, by Product (2021-2034)

10.3.2. Market Revenue and Forecast, by End User (2021-2034)

10.3.3. India

10.3.3.1. Market Revenue and Forecast, by Product (2021-2034)

10.3.3.2. Market Revenue and Forecast, by End User (2021-2034)

10.3.4. China

10.3.4.1. Market Revenue and Forecast, by Product (2021-2034)

10.3.4.2. Market Revenue and Forecast, by End User (2021-2034)

10.3.5. Japan

10.3.5.1. Market Revenue and Forecast, by Product (2021-2034)

10.3.5.2. Market Revenue and Forecast, by End User (2021-2034)

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Forecast, by Product (2021-2034)

10.3.6.2. Market Revenue and Forecast, by End User (2021-2034)

10.4. MEA

10.4.1. Market Revenue and Forecast, by Product (2021-2034)

10.4.2. Market Revenue and Forecast, by End User (2021-2034)

10.4.3. GCC

10.4.3.1. Market Revenue and Forecast, by Product (2021-2034)

10.4.3.2. Market Revenue and Forecast, by End User (2021-2034)

10.4.4. North Africa

10.4.4.1. Market Revenue and Forecast, by Product (2021-2034)

10.4.4.2. Market Revenue and Forecast, by End User (2021-2034)

10.4.5. South Africa

10.4.5.1. Market Revenue and Forecast, by Product (2021-2034)

10.4.5.2. Market Revenue and Forecast, by End User (2021-2034)

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Forecast, by Product (2021-2034)

10.4.6.2. Market Revenue and Forecast, by End User (2021-2034)

10.5. Latin America

10.5.1. Market Revenue and Forecast, by Product (2021-2034)

10.5.2. Market Revenue and Forecast, by End User (2021-2034)

10.5.3. Brazil

10.5.3.1. Market Revenue and Forecast, by Product (2021-2034)

10.5.3.2. Market Revenue and Forecast, by End User (2021-2034)

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Forecast, by Product (2021-2034)

10.5.4.2. Market Revenue and Forecast, by End User (2021-2034)

Chapter 11. Company Profiles

11.1. Cardinal Health Inc.

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. Trinity Biotech

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. Bio-Rad Laboratories Inc.

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. Thermo Fisher Scientific Inc.

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. Quest Diagnostics Incorporated

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. Quidel Corporation

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. Abbott Laboratories

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. Mesa Biotech

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. F. Hoffmann-La Roche Ltd

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. Cepheid

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client